論文

査読有り 国際誌
2019年3月1日

Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer.

Cancer letters
  • Sho Takeda
  • Kunitoshi Shigeyasu
  • Yoshinaga Okugawa
  • Kazuhiro Yoshida
  • Yoshiko Mori
  • Shuya Yano
  • Kazuhiro Noma
  • Yuzo Umeda
  • Yoshitaka Kondo
  • Hiroyuki Kishimoto
  • Fuminori Teraishi
  • Takeshi Nagasaka
  • Hiroshi Tazawa
  • Shunsuke Kagawa
  • Toshiyoshi Fujiwara
  • Ajay Goel
  • 全て表示

444
開始ページ
127
終了ページ
135
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.canlet.2018.12.009
出版者・発行元
ELSEVIER IRELAND LTD

Adenosine-to-inosine (A-to-I) RNA editing is a recently described epigenetic modification, which is believed to constitute a key oncogenic mechanism in human cancers. However, its functional role in cancer-associated fibroblasts (CAFs) within the tumor microenvironment (TME) and its clinical significance remains unclear. Herein, we systematically analyzed a large cohort of 627 colorectal cancer (CRC) specimens, and investigated the expression pattern of ADAR1 and its biological significance on the antizyme inhibitor 1 (AZIN1) RNA editing levels. Both ADAR1 expression and AZIN1 RNA editing levels were significantly elevated in CRC tissues vs. normal mucosa, and these findings correlated with the increased expression of mesenchymal markers, Vimentin (ρ = 0.44) and Fibroblast activation protein (ρ = 0.38). Intriguingly, ADAR1 expression was specifically upregulated in both cancer cells and fibroblasts from cancerous lesions. Conditioned medium from cancer cells led to induction of ADAR1 expression and activation of AZIN1 RNA editing in fibroblasts (p < 0.05). Additionally, edited AZIN1 enhanced the invasive potential of fibroblasts. In conclusion, we provide novel evidence that hyper-editing of AZIN1 enhances the invasive potential of CAFs within the TME in colon and is an important predictor of tumor invasiveness in CRC.

リンク情報
DOI
https://doi.org/10.1016/j.canlet.2018.12.009
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/30583079
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339593
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000457505400012&DestApp=WOS_CPL
ID情報
  • DOI : 10.1016/j.canlet.2018.12.009
  • ISSN : 0304-3835
  • eISSN : 1872-7980
  • PubMed ID : 30583079
  • PubMed Central 記事ID : PMC6339593
  • Web of Science ID : WOS:000457505400012

エクスポート
BibTeX RIS